Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2019-04-10 Major Shareholding Noti…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the changes in share ownership by Neoplux and its related funds in the company 'PharmAbcine'. This type of filing is a mandatory disclosure of significant shareholding changes and falls under the category of Major Shareholding Notification.
2019-04-10 Korean
사업보고서 (2018.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the fiscal year 2018 (2018.01.01-2018.12.31) for PharmAbcine Inc. It contains detailed financial information, company overview, management discussion, and capital structure, which corresponds to the standard format of an Annual Report (10-K equivalent in the Korean market). FY 2018
2019-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the results of a General Meeting of Shareholders (정기주주총회결과). It details the outcomes of voting on agenda items such as financial statement approval, dividend decisions, and director compensation. This falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2019-03-28 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) submitted to the Korea Exchange (KRX). It provides the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and details regarding the external auditor (Samjong Accounting Corp). While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and filing of the audit report, rather than the full annual report document itself. Therefore, it is classified as an Audit Report / Information filing. FY 2018
2019-03-20 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for PharmAbcine. It contains the meeting agenda, details on voting, director activity reports, and financial statements (balance sheet/income statement) for the 11th fiscal year. This document is a standard proxy statement/notice sent to shareholders to inform them of the upcoming meeting and provide necessary information for voting on agenda items. In the context of the provided categories, this fits the definition of a Proxy Solicitation & Information Statement.
2019-03-13 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date'. It explains the company's inability to avoid this date due to audit report timelines and management schedules. As it is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves, proxy statements, or voting results, it falls under the general regulatory filing category.
2019-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.